Reuters -- Ariad Pharmaceuticals Inc said an independent committee of experts recommended that a late-stage trial of the company’s experimental cancer treatment may continue, sending its shares up 12 percent.
Reuters -- Ariad Pharmaceuticals Inc said an independent committee of experts recommended that a late-stage trial of the company’s experimental cancer treatment may continue, sending its shares up 12 percent.
